BTMD

biote is a classic deep-value setup masquerading behind ugly headline optics. The stock trades at 0.4x sales and a 2.9x P/E, with a ~$67.9M market cap against $35.2M of operating cash flow and only $5.0M of capex — roughly $30M of free cash flow, or about 5x EV/FCF once you add the ~$102M of debt and net out $24.1M of cash. The business is genuinely cash-generative: operating income grew 12.5% to $35.6M and operating margin is a healthy 18.5%. Management is using that cash sensibly for a small-cap — repurchasing stock (share count down 8.7%), retiring debt (long-term debt down 5.4%), and paying a modest dividend. At this price the market is pricing in decline or distress.

The caution flags are real and keep this from being a high-conviction buy. First, revenue actually fell 2.5% to $192M and is now below FY2024's $197M — the top line has plateaued. The MD&A explains the structural reason: the MSAs carry 'tiered pricing provisions' where management fees *decrease* as clinics treat more new patients, so revenue from existing Biote-partnered clinics naturally erodes unless offset by net new clinics. That is a built-in headwind to durability, not a one-off. Second, the $27.0M net income (+756.7%) and $0.74 EPS (+722.2%) massively outrun the 12.5% operating-income growth, meaning most of the earnings jump is below-the-line (likely tax and/or fair-value/liability remeasurement common to SPAC-legacy structures), so the 2.9x P/E flatters reality — FCF is the truer yardstick.